The aim of the present study was to increase the solubility and thereby improve the oral bioavailability of Furosemide by incorporating the drug in nanostructured lipid carriers (NLC) and in solid lipid nanoparticle (SLN) and also to compare the efficiency of NLC over SLN. Both the NLC and SLN were prepared by solvent diffusion method using labrafil m 2130 as solid lipid, capryol pgmc as liquid lipid, and tween 80 as surfactant. Properties of Furosemide loaded NLCs & SLNs such as drug content, entrapment efficiency, loading capacity, particle size, PDI , zeta potential, morphology, storage stability, in vitro drug release and mechanism of drug release were investigated and compared. Drug content, entrapment efficiency, loading capacity, average particle size, PDI and zeta potential of Furosemide NLC were found to 83.56%, 75.50%, 25.63%, 99.24nm, 0.302 and -31.2mV and that of Furosemide SLN were found to 84.55%, 71.07%, 24.62%, 193.4nm, 0.835 and -36.1mV respectively. Morphology study by scanning electron microscopy (SEM) analysis showed spherical particles with smooth surfaces. As compared to in-vitro drug release of Furosemide pure drug, both the NLC and SLN showed fast initial release followed by a sustained release, best fitted to Higuchi equation. Pure drug followed Zero order release kinetics. Furosemide NLC showed higher entrapment efficiency, drug loading capacity, in-vitro drug release, reduced the drug expulsion in storage when compared to SLN. This investigation demonstrated the efficiency of NLC over SLN for improved oral bioavailability of Furosemide and it was deduced that the liquid lipid (capryol pgmc)was the principal formulation factor responsible for the improvement in characteristics and pharmacokinetics of NLCs.